Combined inhibition of mTORC1 with temsirolimus and HER2 with neratinib: A phase I study in patients with metastatic HER2-amplified breast cancer.

被引：2
|
作者：
Gajria, D. [1 ]
King, T. A. [1 ]
Pannu, H. [1 ]
Sakr, R. [1 ]
Seidman, A. D. [1 ]
Syldor, A. [1 ]
Patil, S. [1 ]
Maybody, M. [1 ]
Norton, L. [1 ]
Rosen, N. [1 ]
Hudis, C. [1 ]
Chandarlapaty, S. [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.574
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
574
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Combined Inhibition of mTORC1 with Temsirolimus and HER2 with Neratinib: A Phase I/II Study in Patients with Metastatic HER2-Amplified or Triple-Negative Breast Cancer.
    Gajria, D.
    King, T.
    Pannu, H.
    Sakr, R.
    Seidman, A. D.
    Modi, S.
    Dickler, M.
    Drullinsky, P.
    Syldor, A.
    Sujata, P.
    Majid, M.
    Norton, L.
    Rosen, N.
    Chandarlapaty, S.
    CANCER RESEARCH, 2011, 71
  • [2] Phase II study of neratinib in older adults with HER2 amplified or HER2/3 mutated metastatic breast cancer
    Yuan, Yuan
    Lee, Jin Sun
    Yost, Susan E.
    Stiller, Tracey
    Blanchard, M. Suzette
    Padam, Simran
    Katheria, Vani
    Kim, Heeyoung
    Sun, Canlan
    Tang, Aileen
    Martinez, Norma
    Patel, Niki Dipesh
    Sedrak, Mina S.
    Waisman, James
    Li, Daneng
    Sanani, Shamel
    Presant, Cary A.
    Mortimer, Joanne
    JOURNAL OF GERIATRIC ONCOLOGY, 2021, 12 (05) : 752 - 758
  • [3] Tolerability of neratinib in older adults with HER2 positive or HER2 mutated metastatic breast cancer.
    Lee, Jin Sun
    Yost, Susan Elaine
    Stiller, Tracey
    Blanchard, Suzette
    Padam, Simran
    Katheria, Vani
    Tang, Aileen
    Martinez, Norma
    Patel, Niki Himat
    Sedrak, Mina S.
    Waisman, James Ross
    Li, Daneng
    Sanani, Shamel
    Presant, Cary A.
    Mortimer, Joanne E.
    Yuan, Yuan
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [4] BCIRG 007: Serum HER2 levels in women with metastatic HER2-amplified breast cancer
    Sampson, E. L.
    Valero, V.
    Roche, H.
    Pienkowski, T.
    Canon, J.
    Zhao, Y.
    Carney, W.
    Mackey, J.
    Taupin, H.
    Lindsay, M.
    Buyse, M.
    Slamon, D.
    CLINICAL CHEMISTRY, 2007, 53 (06) : A34 - A34
  • [5] BCIRG 007: Serum HER2 levels in women with metastatic HER2-amplified breast cancer
    Valero, V.
    Roche, H.
    Pienkowski, T.
    Canon, J.
    Zhao, Y.
    Carney, W.
    Mackey, J.
    Taupin, H.
    Buyse, M.
    Slamon, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [6] Neratinib has clinical activity in HER2-amplified breast cancer patients with tumors that have acquired activating mutations in HER2
    Cocco, Emiliano
    Carmona, F. Javier
    Won, Helen H.
    Berger, Michael F.
    Hyman, David M.
    Rossi, Valentina
    Chan, Carmen
    Moriarty, Alyssa
    Papadopoulos, Kyriakos P.
    Wick, Michael J.
    Cownie, James
    Sarotto, Ivana
    Cutler, Richard E.
    Avogadri-Connors, Francesca
    Savas, Peter
    Lalani, Alshad S.
    Boni, Valentina
    Loi, Sherene
    Baselga, Jose
    Montemurro, Filippo
    Scaltriti, Maurizio
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
  • [7] Combinatorial therapies of neratinib for HER2-amplified cancer
    Zhao, Ming
    Scott, Stephen
    Evans, Kurt
    Yuca, Erkan
    Saridogan, Turcin
    Demirhan, Mehmet E.
    Kirby, Bryce P.
    Kopetz, Scott
    Diala, Irmina
    Lalani, Alshad S.
    Piha-Paul, Sarina A.
    Meric-Bernstam, Funda
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (12)
  • [8] A phase I/II study of neratinib plus temsirolimus in HER2+metastatic breast cancer reveals ongoing HER2 pathway dependence in many patients despite several lines of HER2 targeted therapy
    Gajria, Devika
    Modi, Shanu
    Saura, Cristina
    Sakr, Rita
    Solano, Karl
    Won, Helen
    Pannu, Harpreet
    Patil, Sujata
    Lake, Diana
    Traina, Tiffany
    King, Tari
    Berger, Michael
    Baselga, Jose
    Rosen, Neal
    Hudis, Cliff
    Chandarlapaty, Sarat
    CANCER RESEARCH, 2015, 75
  • [9] Phase II trial of neratinib for HER2 mutated, non-amplified metastatic breast cancer (HER2mut MBC).
    Ma, Cynthia X.
    Bose, Ron
    Gao, Feng
    Freedman, Rachel A.
    Pegram, Mark D.
    Blackwell, Kimberly
    Bedard, Philippe L.
    Hayes, Daniel F.
    Goetz, Matthew P.
    Niravath, Polly Ann
    Russell, Christy Ann
    Tripathy, Debu
    Cobleigh, Melody A.
    Forero, Andres
    Pluard, Timothy J.
    Anders, Carey K.
    Bumb, Caroline
    Naughton, Michael
    Al-Kateb, Hussam
    Ellis, Matthew James
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [10] Combined targeting of HER2 and VEGFR2 for effective treatment of HER2-amplified breast cancer brain metastases
    Kodack, David P.
    Chung, Euiheon
    Yamashita, Hiroshi
    Incio, Joao
    Duyverman, Annique M. M. J.
    Song, Youngchul
    Farrar, Christian T.
    Huang, Yuhui
    Ager, Eleanor
    Kamoun, Walid
    Goel, Shom
    Snuderl, Matija
    Lussiez, Alisha
    Hiddingh, Lotte
    Mahmood, Sidra
    Tannous, Bakhos A.
    Eichler, April F.
    Fukumura, Dai
    Engelman, Jeffrey A.
    Jain, Rakesh K.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2012, 109 (45) : E3119 - E3127
12345